Wen-hong Q. Zhang

12 Middle Urumqi Road
Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 116 publications

Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controlled Trial (SPHERE) Protocol.

Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controlled Trial (SPHERE) Protocol.

Journal: Advances in therapy

Published: February 06, 2026

A bidimensional early intervention strategy of standard of care in combination with corticosteroids in elderly patients with mild to moderate COVID-19 (BEAT-COV study): a multicentre, open-label, randomized controlled trial.

A bidimensional early intervention strategy of standard of care in combination with corticosteroids in elderly patients with mild to moderate COVID-19 (BEAT-COV study): a multicentre, open-label, randomized controlled trial.

Journal: BMC infectious diseases

Published: December 01, 2025

Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China.

Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China.

Journal: BMC infectious diseases

Published: November 15, 2025

Sputum-negative pulmonary tuberculosis in Shanghai, China: notification, clinical characteristics and outcomes.

Sputum-negative pulmonary tuberculosis in Shanghai, China: notification, clinical characteristics and outcomes.

Journal: BMC infectious diseases

Published: September 08, 2025

Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB).

Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB).

Journal: Emerging microbes & infections

Published: May 06, 2025

Spectrum, dose, and duration of antibiotic exposure and risk of intensive care unit-acquired carbapenem-resistant gram-negative bacteria: a prospective cohort study.

Spectrum, dose, and duration of antibiotic exposure and risk of intensive care unit-acquired carbapenem-resistant gram-negative bacteria: a prospective cohort study.

Journal: Annals of intensive care

Published: May 06, 2025

TELLBASE: a novel tool of TELL-seq barcode-assisted scaffold assembler for bacterial genomes.

TELLBASE: a novel tool of TELL-seq barcode-assisted scaffold assembler for bacterial genomes.

Journal: Briefings in bioinformatics

Published: March 04, 2025

Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks.

Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks.

Journal: Hepatology international

Published: September 13, 2024

Patient pathway analysis of rifampicin-resistant TB diagnostic and treatment delays.

Patient pathway analysis of rifampicin-resistant TB diagnostic and treatment delays.

Journal: IJTLD open

Published: September 09, 2024

DeepPBI-KG: a deep learning method for the prediction of phage-bacteria interactions based on key genes.

DeepPBI-KG: a deep learning method for the prediction of phage-bacteria interactions based on key genes.

Journal: Briefings in bioinformatics

Published: May 30, 2024

PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial.

PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial.

Journal: Journal of hepatology

Published: January 15, 2024

Correction to: Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study.

Correction to: Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study.

Journal: Hepatology international

Published: September 22, 2023

Showing 1-12 of 116

Last Updated: 09/26/2026